Sixpex supplies this semaglutide pen alternative as a 5 mg compounded injectable in a 3 ml vial, manufactured for subcutaneous administration where a syringe is used in place of an automatic delivery device. The single-vial format suits buyers weighing low dose semaglutide options across labs, comparing labelled strength and milliliter volume before selecting a supplier.

5 mg Semaglutide in a 3 ml Vial

The vial states 5 mg total peptide across 3 ml, a lower absolute content than the Ultima Pharmaceuticals 10 mg listing but held in the same 3 ml volume. Compounded preparations like this one are sourced and manufactured independently of branded pharmaceutical lines, differing in packaging and distribution rather than in the peptide sequence itself. Storage requires refrigeration once reconstituted, with shelf life detailed on the vial label.

Sixpex Beside Ultima Pharmaceuticals and Crowx Labs

Where Ultima Pharmaceuticals bottles 10 mg in 3 ml and Crowx Labs lists Semagrow 10 at the same strength, this Sixpex vial carries half that peptide load in identical volume. Buyers prioritising 0.25 semaglutide increments in early titration phases often select the 5 mg concentration to limit waste, while those progressing beyond initial steps may choose the 10 mg option to reduce vial turnover. Sixpex, based in the USA and producing these since 2024, manufactures this as part of a compounded peptide range that includes other body fat burners in injectable and oral forms.